The 5 key players our Pulmonary Arterial Hypertension Drugs report profiles, and other companies free public records show in this market.
In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.
| # | Company | Website | Our reports |
|---|---|---|---|
| 1 | Johnson & Johnson |
jnj.com (opens in a new tab) | 2,526 reports |
| 2 | Merck & Co., Inc. |
merck.com (opens in a new tab) | 1,470 reports |
| 3 | United Therapeutics | — | 66 reports |
| 4 | Bayer AG |
bayer.com (opens in a new tab) | 1,370 reports |
| 5 | Liquidia | — | 33 reports |
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
| Company | Where public records show them |
|---|---|
Aurobindo Pharma |
|
| Zydus Lifesciences | |
| Insmed Incorporated |
|
Teva Pharmaceutical |
|
| Ajanta Pharma Ltd | |
| Eko Devices, Inc. |
|
| Chartwell RX | |
| Novlead Inc. |
|
| Mylan N.V. | |
| Pulmovant, Inc. |
|
| AOP Orphan Pharmaceuticals AG |
|
Sun Pharmaceutical Industries Ltd. |
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Companies leading the most active studies found with this market's trial search, worldwide (key players included).
Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
One report for each place. Each tile opens that place's report.
Compare all 33 places for Pulmonary Arterial Hypertension Drugs, with active trials
Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.
Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.